Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 9/20 | 0.44 |
| ▸ | MAOB | P27338 | 9/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460835 | 0.93 | MEN1 (0.49) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL1275258 | 0.84 | MEN1 (0.55) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL5372286 | 0.84 | MEN1 (0.55) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL12093250 | 0.81 | HSD17B1 (0.44) | MEN1MAPK1KMT2ANPSR1HSD17B1 | |
| SCHEMBL10389435 | 0.80 | MEN1 (0.50) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL10389430 | 0.80 | MEN1 (0.50) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL16858594 | 0.78 | MAPK1 (0.49) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL21982870 | 0.78 | MAOA (0.53) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL1027553 | 0.78 | MAPK1 (0.49) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL10102252 | 0.78 | MAOA (0.53) | MEN1MAPK1KMT2ANPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375594-A | Preparation process of irinotecan intermediate | 山东恒屹生物医药有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-20230257392-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI HAOYUAN MEDCHEMEXPRESS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257392-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI HAOYUAN MEDCHEMEXPRESS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-116375594-A | Preparation process of irinotecan intermediate | 山东恒屹生物医药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11318212-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-03 | — | — | US | disclosed |
| WO-2022000868-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海皓元生物医药科技有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-20200384121-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3677568-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-08 | — | — | EP | disclosed |
| EP-0811603-B1 | AMINOTETRALONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-5849945-A | Aminotetralone derivatives and preparation process thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0811603-A1 | AMINOTETRALONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384121-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | CD79B, FCGRT, FURIN | MEN1 287/4885MAPK1 3171/4885KMT2A 1530/4885 |
| US-20230257392-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE1, WEE2, FAR1 | MEN1 69/4885MAPK1 2597/4885KMT2A 563/4885 |
| US-11318212-B2 | Method for producing antibody-drug conjugate | CD79B, FCGRT, C1R | MEN1 180/4885MAPK1 3381/4885KMT2A 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.